High quality products to support Pathologists and Biological and Environmental Scientists
GeneAb™ HBsAg
$85.00 – $350.00Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
GeneAb™ Ki-67
$75.00 – $340.00Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
GeneAb™ CD163
$100.00 – $455.00Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
GeneAb™ OX40
$235.00 – $915.00OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that the OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumour immunity of several cancer types.
GeneAb™ CD30
$70.00 – $305.00Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin’s lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
GeneAb™ B7H4
$210.00 – $980.00B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
GeneAb™ LAG3
$100.00 – $455.00LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumour infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumour stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
GeneAb™ CD99
$110.00 – $635.00Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing’s sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.